DHAP in context of chemotherapy is an acronym for chemotherapy regimen that is used for remission induction in cases of relapsed or refractory non-Hodgkin lymphoma and Hodgkin's lymphoma. It is usually given for 2-3 courses, then followed by high-dose chemotherapy and autologous stem cell transplantation. In combination with anti-CD20 monoclonal antibody rituximab (Rituxan, Mabthera) it is called R-DHAP or DHAP-R.
[R]-DHAP regimen consists of:
- Rituximab, a monoclonal antibody, directed at B-cell surface antigen CD20
- (D)examethasone, a glucocorticoid hormone
- (H)igh-dose (A)ra-C - cytarabine, an antimetabolite;
- (P)latinol (cisplatin), a platinum-based antineoplastic, also an alkylating antineoplastic agent.
|(R)ituximab||375 mg/m2||IV infusion||Day 0|
|(D)examethasone||40 mg||PO qd||Days 1-4|
|(H)igh-dose Ara-C - cytarabine||2000 mg/m2||IV infusion over 2 hrs||Day 2, every 12 hours|
|(P)latinol (cisplatin)||100 mg/m2||IV infusion over 24 hrs||Day 1|